MeSH Browser

MeSH Heading: Brimonidine Tartrate
Tree Number(s): D03.633.100.857.070
Unique ID: D000068438
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D000068438
Scope Note: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
Entry Term(s): 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate; 5-bromo-6-(imidazolidinylideneamino)quinoxaline; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; AGN 190342; AGN-190342; Alphagan; Alphagan P; Brimonidine; Brimonidine Purite; Brimonidine Tartrate (1:1); Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer; Brimonidine Tartrate, (R-(R*,R*))-Isomer; Bromoxidine; Mirvaso; Ratio-Brimonidine; Sanrosa; UK 14,304; UK 14,304-18; UK 14304; UK 14308; UK-14,304-18; UK-14,308; UK-14304
Pharm Action: Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Registry Number: 4S9CL2DY2H
Related Numbers: 59803-98-4; 59803-99-5; 70359-46-5; 79570-19-7; E6GNX3HHTE
CAS Type 1 Name: 6-quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
Public MeSH Note: 2016; BRIMONIDINE TARTRATE was indexed under QUINOXALINES 1980-2015, and under IMIDAZOLES 1978-1980
History Note: 2016 (1978)
Date Established: 2016/01/01
Date of Entry: 2015/07/01
Revision Date: 2018/05/21

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Brimonidine Tartrate MeSH Descriptor Data 2024